You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 8,217,057

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,217,057

Title:	Polymorphs of a c-MET/HGFR inhibitor
Abstract:	This invention relates to polymorphs of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-py- razol-4-yl)-pyridin-2-ylamine that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to compositions including such salts and polymorphs, and to methods of using such compositions in the treatment of abnormal cell growth in mammals, especially humans.
Inventor(s):	Cui; Jingrong Jean (San Diego, CA), Tran-Dube; Michelle Bich (San Diego, CA)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	12/095,116
Patent Claims:	1. A crystalline form of free base of (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyr- azol-4-yl)-pyridin-2-ylamine having a powder X-ray diffraction pattern substantially the same as shown in FIG. 1. 2. The crystalline form of claim 1, wherein the powder X-ray diffraction pattern has a peak at diffraction angle (2.theta.) of 19.7.+-.0.1. 3. The crystalline form of claim 1, wherein the powder X-ray diffraction pattern has peaks at diffraction angles (2.theta.) of 17.3.+-.0.1 and 19.7.+-.0.1. 4. The crystalline form of claim 1, wherein the powder X-ray diffraction pattern has peaks at diffraction angles (2.theta.) of 15.7.+-.0.1, 17.3.+-.0.1, and 19.7.+-.0.1. 5. The crystalline form of claim 1, wherein the powder X-ray diffraction pattern has peaks at diffraction angles (2.theta.) of 15.7.+-.0.1, 17.3.+-.0.1, 19.7.+-.0.1, and 26.8.+-.0.1. 6. A pharmaceutical composition comprising the crystalline form of claim 1. 7. A capsule comprising the pharmaceutical composition of claim 6. 8. The capsule of claim 7 comprising from 0.1 to 200 mg of the crystalline form of (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-py- razol-4-yl)-pyridin-2-ylamine. 9. The capsule of claim 7 comprising from 25 to 150 mg of the crystalline form of (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-- yl-1H-pyrazol-4-yl)-pyridin-2-ylamine. 10. The capsule of claim 7 comprising from 50 to 100 mg of the crystalline form of (R)-3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-py- razol-4-yl)-pyridin-2-ylamine.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.